

Remarks


Claims 1-82, 84, 85, 87, 88, 91-99, and 103-129 have been canceled. Claims 83, 86, 89, 90, 100-102 remain after amendment. Claims 130-145 have been added.

The Examiner imposed a restriction requirement between groups I-V. Applicants elect Group IV (claim 89), without traverse. Claims 83, 86, 90, 100, 101, and 102 as amended and newly added claims 130-145 fall within the elected group IV. Thus, examination of claims 83, 86, 90, 100, 101, 102, and 130-145 is required.

The Examiner has additionally required an election of species between groups 1-7. Applicants elect the species directed to pyrimidines. Claims 83, 86, 89, 90, 100-102 and 130-145 read on the elected species.

The unifying concept in the remaining claims is that each is a pyrimidine nucleoside that has two non-hydrogen substituents in the 2'-position of the nucleoside, which represents the core of the invention. Applicants are not aware of any prior disclosure of the use of a pyrimidine nucleoside with a "2'-branched" carbon to treat these viruses.

Respectfully submitted,




Sherry M. Knowles, Esq.
Registration No. 33,052

Date: June 6, 2003

King & Spalding
191 Peachtree Street
Atlanta, Georgia 30303
Telephone: 404-572-3541
Facsimile: 404-572-5145

CERTIFICATE OF MAILING UNDER 37 CFR § 1.8 (a)

I hereby certify that this Amendment and Response to Restriction Requirement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Commissioner for Patents, PO Box 1450, Alexandria, VA, 22313-1450.



Hoang Vo

Date: June 6, 2003